A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

The impact of flare on disease costs of patients with systemic lupus erythematosus

(2009) Tracy Y. Zhu et al.   ARTHRITIS AND RHEUMATISM

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

(2009) Annett M. Jacobi et al.   ARTHRITIS AND RHEUMATISM

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

(2009) Michael P. Cancro et al.   JOURNAL OF CLINICAL INVESTIGATION

The socioeconomic burden of SLE

(2009) Chak Sing Lau et al.   Nature Reviews Rheumatology

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM